Moderna, Inc.
MRNAFull coverage—Moderna, Inc.
MRNANasdaqFull coverage
Q3 fiscal 2026 edition
A free account unlocks one dossier edition a month.
Create a free accountAlready have an account? Sign in
Summary
Free to read
Moderna sells mRNA vaccines against COVID-19, RSV and flu to US wholesalers and pharmacies and to governments abroad, and shares with Merck an individualised cancer therapy, intismeran, that met its Phase 3 goals in melanoma in 2026. Third-quarter 2026 revenue rose 29% to $1.3 billion, all of the growth from multi-year contracts with the UK, Canada and Australia, while US sales were flat and costs fell by about a fifth. The raised 2026 outlook implies a much weaker fourth quarter, and free cash flow over the last twelve months was minus $1.97 billion. Moatsight estimates revenue of about $2.47 billion over the next four quarters and free cash flow of about minus $1.36 billion, so how large intismeran becomes is what decides the company's future.
In the full dossier
- Part 1In brief
- Part 2Business explainer
- Part 3Earnings
- Part 4Valuation and projections
- Part 5What changed
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers